Arkolith/Insider Trading/ACAD/Form 4

Schneyer Mark C.

EVP, CHIEF FINANCIAL OFFICERACADIA PHARMACEUTICALS INC (ACAD) · full profile →Form 4 · filed Mar 10, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 6, 2026Grant(A)26K—$026K
Mar 6, 2026Grant(A)91K—$091K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001899977-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML